Blood-brain barrier endogenous transporters as therapeutic targets: A new model for small molecule CNS drug discovery

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 8, 2015, Pages 1059-1072

  Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; carrier mediated transport; small molecules; solute carrier transporter genes

Indexed keywords

AMINO ACID TRANSPORTER; CARRIER PROTEINS AND BINDING PROTEINS; CENTRAL NERVOUS SYSTEM AGENTS; GLUCOSE TRANSPORTER; GLUCOSE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER; MONOCARBOXYLATE TRANSPORTER 1; THYROID HORMONE; CARRIER PROTEIN; DRUG; LIPID; MOLECULAR LIBRARY;

ACTIVE TRANSPORT; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; DRUG PENETRATION; DRUG SCREENING; DRUG TARGETING; DRUG TRANSPORT; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MOLECULAR CLONING; MOLECULAR LIBRARY; NERVE CELL; NONHUMAN; REVIEW; ANIMAL; BRAIN; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; GENETICS; METABOLISM; SOLUBILITY; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BRAIN; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; LIPIDS; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; SMALL MOLECULE LIBRARIES; SOLUBILITY;

EID: 84937121327     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1042364     Document Type: Review

References (72)

1. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2005;2(1):3-14
2. Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J Comb Chem 1999;1(1):55-68
3. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44(1):235-49
4. Fischer H, Gottschlich R, Seelig A. Blood-brain barrier permeation: molecular parameters governing passive diffusion. J Membr Biol 1998;165(3):201-11
5. Kageyama T, Nakamura M, Matsuo A, et al. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Res 2000;879(1-2):115-21
6. Dickens D, Webb SD, Antonyuk S, et al. Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol 2013;85(11):1672-83
7. Cornford EM, Young D, Paxton JW, et al. Melphalan penetration of the blood-brain barrier via the neutral amino acid transporter in tumor-bearing brain. Cancer Res 1992;52(1):138-43
8. Hediger MA, Clemencon B, Burrier RE, et al. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol Aspects Med 2013;34(2-3):95-107
9. Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood-brain barrier. Studies with quantitative western blotting and in situ hybridization. J Biol Chem 1990;265(29):18035-40
10. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (Pglycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86(2):695-8
11. Boado RJ, Pardridge WM. Differential expression of alpha-actin mRNA and immunoreactive protein in brain microvascular pericytes and smooth muscle cells. J Neurosci Res 1994;39(4):430-5
12. Pardridge WM, Yang J, Buciak J, et al. Human brain microvascular DR-antigen. J Neurosci Res 1989;23(3):337-41
13. Golden PL, Pardridge WM. P-Glycoprotein on astrocyte foot processes of unfixed isolated human brain capillaries. Brain Res 1999;819(1-2):143-6
14. Pardridge WM, Yang J, Buciak JL, et al. Differential expression of 53-and 45-kDa brain capillary-specific proteins by brain capillary endothelium and choroid plexus in vivo and by brain capillary endothelium in tissue culture. Mol Cell Neurosci 1990;1(1):20-8
15. Schlachetzki F, Pardridge WM. P-glycoprotein and caveolin-1alpha in endothelium and astrocytes of primate brain. Neuroreport 2003;14(16):2041-6
16. Cornford EM, Hyman S, Cornford ME, et al. Glut1 glucose transporter activity in human brain injury. J Neurotrauma 1996;13(9):523-36
17. Pardridge WM, Triguero D, Yang J, et al. Comparison of in vitro and in vivo models of drug transcytosis through the blood-brain barrier. J Pharmacol Exp Ther 1990;253(2):884-91
18. Urich E, Lazic SE, Molnos J, et al. Transcriptional profiling of human brain endothelial cells reveals key properties crucial for predictive in vitro blood-brain barrier models. PLoS One 2012;7(5):e38149
19. Oldendorf WH. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am J Physiol 1971;221(6):1629-39
20. Takasato Y, Rapoport SI, Smith QR. An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol 1984;247(3 Pt 2):H484-93
21. Kakee A, Terasaki T, Sugiyama Y. Brain efflux index as a novel method of analyzing efflux transport at the bloodbrain barrier. J Pharmacol Exp Ther 1996;277(3):1550-9
22. Dwyer KJ, Pardridge WM. Developmental modulation of bloodbrain barrier and choroid plexus GLUT1 glucose transporter messenger ribonucleic acid and immunoreactive protein in rabbits. Endocrinology 1993;132(2):558-65
23. Hoshi Y, Uchida Y, Tachikawa M, et al. Quantitative atlas of blood-brain barrier transporters, receptors, and tight junction proteins in rats and common marmoset. J Pharm Sci 2013;102(9):3343-55
24. Uchida Y, Ohtsuki S, Katsukura Y, et al. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors. J Neurochem 2011;117(2):333-45
25. Pardridge WM, Oldendorf WH. Kinetics of blood-brain transport of hexoses. Biochim Biophys Acta 1975;382(3):377-92
26. Crane PD, Pardridge WM, Braun LD, et al. Kinetics of transport and phosphorylation of 2-fluoro-2-deoxy-Dglucose in rat brain. J Neurochem 1983;40(1):160-7
27. Cremer JE, Cunningham VJ. Effects of some chlorinated sugar derivatives on the hexose transport system of the blood/brain barrier. Biochem J 1979;180(3):677-9
28. Gerhart DZ, Enerson BE, Zhdankina OY, et al. Expression of monocarboxylate transporter MCT1 by brain endothelium and glia in adult and suckling rats. Am J Physiol 1997;273(1 Pt 1):E207-13
29. Oldendorf WH. Carrier-mediated bloodbrain barrier transport of short-chain monocarboxylic organic acids. Am J Physiol 1973;224(6):1450-3
30. Pardridge WM, Connor JD, Crawford IL. Permeability changes in the blood-brain barrier: causes and consequences. CRC Crit Rev Toxicol 1975;3(2):159-99
31. Cremer JE, Cunningham VJ, Pardridge WM, et al. Kinetics of bloodbrain barrier transport of pyruvate, lactate and glucose in suckling, weanling and adult rats. J Neurochem 1979;33(2):439-45
32. Halestrap AP. Monocarboxylic acid transport. Compr Physiol 2013;3(4):1611-43
33. Kirk P, Wilson MC, Heddle C, et al. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 2000;19(15):3896-904
34. Uchida Y, Ohtsuki S, Terasaki T. Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models. Drug Metab Dispos 2014;42(10):1719-26
35. Pardridge WM, Oldendorf WH. Kinetic analysis of blood-brain barrier transport of amino acids. Biochim Biophys Acta 1975;401(1):128-36
36. Pardridge WM, Oldendorf WH. Transport of metabolic substrates through the blood-brain barrier. J Neurochem 1977;28(1):5-12
37. Pardridge WM. Kinetics of competitive inhibition of neutral amino acid transport across the blood-brain barrier. J Neurochem 1977;28(1):103-8
38. Kanai Y, Segawa H, Miyamoto K, et al. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 1998;273(37):23629-32
39. Boado RJ, Li JY, Nagaya M, et al. Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA 1999;96(21):12079-84
40. Oldendorf WH, Szabo J. Amino acid assignment to one of three blood-brain barrier amino acid carriers. Am J Physiol 1976;230(1):94-8
41. Smith QR, Momma S, Aoyagi M, et al. Kinetics of neutral amino acid transport across the blood-brain barrier. J Neurochem 1987;49(5):1651-8
42. Wade LA, Brady HM. Cysteine and cystine transport at the blood-brain barrier. J Neurochem 1981;37(3):730-4
43. Sanchez del Pino MM, Peterson DR, Hawkins RA. Neutral amino acid transport characterization of isolated luminal and abluminal membranes of the blood-brain barrier. J Biol Chem 1995;270(25):14913-18
44. Stoll J, Wadhwani KC, Smith QR. Identification of the cationic amino acid transporter (System y+) of the rat bloodbrain barrier. J Neurochem 1993;60(5):1956-9
45. Oldendorf WH, Crane PD, Braun LD, et al. pH dependence of histidine affinity for blood-brain barrier carrier transport systems for neutral and cationic amino acids. J Neurochem 1988;50(3):857-61
46. Cornford EM, Braun LD, Oldendorf WH. Carrier mediated bloodbrain barrier transport of choline and certain choline analogs. J Neurochem 1978;30(2):299-308
47. Michel V, Bakovic M. The ubiquitous choline transporter SLC44A1. Cent Nerv Syst Agents Med Chem 2012;12(2):70-81
48. Kido Y, Tamai I, Ohnari A, et al. Functional relevance of carnitine transporter OCTN2 to brain distribution of L-carnitine and acetyl-L-carnitine across the blood-brain barrier. J Neurochem 2001;79(5):959-69
49. Moriki Y, Suzuki T, Furuishi T, et al. In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. J Drug Target 2005;13(1):53-9
50. Cornford EM, Oldendorf WH. Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim Biophys Acta 1975;394(2):211-19
51. Cass CE, Young JD, Baldwin SA. Recent advances in the molecular biology of nucleoside transporters of mammalian cells. Biochem Cell Biol 1998;76(5):761-70
52. Li JY, Boado RJ, Pardridge WM. Cloned blood-brain barrier adenosine transporter is identical to the rat concentrative Na+ nucleoside cotransporter CNT2. J Cereb Blood Flow Metab 2001;21(8):929-36
53. Pardridge WM, Yoshikawa T, Kang YS, et al. Blood-brain barrier transport and brain metabolism of adenosine and adenosine analogs. J Pharmacol Exp Ther 1994;268(1):14-18
54. Berne RM, Knabb RM, Ely SW, et al. Adenosine in the local regulation of blood flow: a brief overview. Fed Proc 1983;42(15):3136-42
55. Wu PH, Phillis JW. Uptake of adenosine by isolated rat brain capillaries. J Neurochem 1982;38(3):687-90
56. Kosti V, Lambrinidis G, Myrianthopoulos V, et al. Identification of the substrate recognition and transport pathway in a eukaryotic member of the nucleobase-ascorbate transporter (NAT) family. PLoS One 2012;7(7):e41939
57. Agus DB, Gambhir SS, Pardridge WM, et al. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. J Clin Invest 1997;100(11):2842-8
58. O'Kane RL, Martinez-Lopez I, DeJoseph MR, et al. Na(+)-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J Biol Chem 1999;274(45):31891-5
59. Pardridge WM. Brain metabolism: a perspective from the blood-brain barrier. Physiol Rev 1983;63(4):1481-535
60. Friesema EC, Ganguly S, Abdalla A, et al. Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem 2003;278(41):40128-35
61. Sugiyama D, Kusuhara H, Taniguchi H, et al. Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine. J Biol Chem 2003;278(44):43489-95
62. Li JY, Boado RJ, Pardridge WM. Blood-brain barrier genomics. J Cereb Blood Flow Metab 2001;21(1):61-8
63. Chu C, Li JY, Boado RJ, Pardridge WM. Blood-brain barrier genomics and cloning of a novel organic anion transporter. J Cereb Blood Flow Metab 2008;28(2):291-301
64. Pardridge WM. Carrier-mediated transport of thyroid hormones through the rat blood-brain barrier: primary role of albumin-bound hormone. Endocrinology 1979;105(3):605-12
65. Pardridge WM, Eisenberg J, Fierer G, et al. Developmental changes in brain and serum binding of testosterone and in brain capillary uptake of testosteronebinding serum proteins in the rabbit. Brain Res 1988;466(2):245-53
66. Mayerl S, Muller J, Bauer R, et al. Transporters MCT8 and OATP1C1 maintain murine brain thyroid hormone homeostasis. J Clin Invest 2014;124(5):1987-99
67. Li JY, Boado RJ, Pardridge WM. Differential kinetics of transport of 2', 3'-dideoxyinosine and adenosine via concentrative Na+ nucleoside transporter CNT2 cloned from rat blood-brain barrier. J Pharmacol Exp Ther 2001;299(2):735-40
68. Pardridge WM. Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012;32(11):1959-72
69. Mejia AA, Nakamura T, Masatoshi I, et al. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med 1991;32:699-706
70. Inoue T, Shibasaki T, Oriuchi N, et al. 18F alpha-methyl tyrosine PET studies in patients with brain tumors. J Nucl Med 1999;40:399-405
71. Pardridge WM. Recent advances in blood-brain barrier transport. Annu Rev Pharmacol Toxicol 1988;28:25-39
72. Ito K, Uchida Y, Ohtsuki S, et al. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci 2011;100(9):3939-50